Filippo Cademartiri: 3 Biomarkers Are Better Than 1: Refining ASCVD Risk in MESA
Filippo Cademartiri, Consultant Advanced Cardiovascular Imaging at UPMC Salvator Mundi International Hospital, shared on LinkedIn:
”Three biomarkers are better than one: refining ASCVD risk in MESA
Traditional risk assessment often treats biomarkers in isolation.
This large analysis from the Multi-Ethnic Study of Atherosclerosis (MESA) shows why that approach may miss the people at highest cardiovascular risk.
What was studied?
Researchers evaluated the individual and combined effects of:
Lipoprotein(a) [Lp(a)]
High-sensitivity CRP (hs-CRP)
Total homocysteine (tHcy)
on coronary heart disease (CHD) and stroke over ~16 years of follow-up in >6,600 asymptomatic adults.
Key findings
Alone, biomarkers showed modest or inconsistent associations.
Risk rose sharply only when biomarkers were elevated together.
Individuals with all three elevated had:
~2× higher risk of CHD
~3× higher risk of stroke
In contrast, having just one elevated marker often did not meaningfully increase risk after adjustment.
Why this matters
This study highlights a core limitation of single-marker thinking:
ASCVD risk is multidimensional
Inflammation, thrombosis, and atherogenesis interact
“Average” risk estimates can obscure high-risk biological phenotypes
Notably, homocysteine—not currently a guideline risk enhancer—emerged as a powerful amplifier of risk when combined with inflammation and Lp(a).
Important nuance
Adding these biomarkers only modestly improved population-level prediction metrics (C-statistics). But for individual risk stratification, the signal is clinically meaningful.
Take-home message
ASCVD risk is not additive—it’s synergistic.
Looking at biomarker combinations, rather than single values, may better identify who truly carries residual cardiovascular risk.
Precision prevention beats one-number medicine.”
Read the full article here.
Article: Lipoprotein(a), high-sensitivity c-reactive protein, homocysteine and cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis
Authors: Sarah O. Nomura, Harpreet S. Bhatia, Parveen K. Garg, Amy B. Karger, Weihua Guan, Jing Cao, Michael D. Shapiro, Michael Y. Tsai
Stay updated on all scientific advances with Hemostasis Today.
-
May 2, 2026, 05:24Aaron Kantambo: The Thrombocytic Lineage in Hemostasis and Vascular Repair
-
May 2, 2026, 05:23Ceeli Thairianathan: Bridging Biotechnology and Clinical Application
-
May 2, 2026, 05:23Ali AlBahar: Ensuring Safety and Precision Across the Blood Transfusion Process
-
May 1, 2026, 17:55Salih Ehsan: The Deceptive Nature of B12 Deficiency Not Just Anemia
-
May 1, 2026, 17:45Angela Blue: Insurance Education as a Tool for Strengthening Patient Communities
-
May 1, 2026, 17:36Smitirupa Mishra: Hematology Formulas Made Simple, Structured, And Useful For Everyday Clinical Practice
-
May 1, 2026, 17:00Frank Weinz: VTE Prevention Strategies and Advances in Clinical Practice
-
May 1, 2026, 16:54Pierre François Sabouret: Women’s Health Should Be a Priority for All HCPs, Not Just WIC
-
May 1, 2026, 16:44Jean Jacques Kiladjian: A Global Triumph in MPN Research at ESHMPN 2026